Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study
Jimmie L. Pirtle, Melissa D. Hickman, Varun C. Boinpelly, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 180, pp. 52-59
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Improving translation of animal models of addiction and relapse by reverse translation
Marco Vènniro, Matthew L. Banks, Markus Heilig, et al.
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 625-643
Closed Access | Times Cited: 181
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Guy A. Higgins, Paul Fletcher, William Shanahan
Pharmacology & Therapeutics (2019) Vol. 205, pp. 107417-107417
Closed Access | Times Cited: 67
Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys
E. Andrew Townsend, S. Stevens Negus, Justin L. Poklis, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107848-107848
Open Access | Times Cited: 30
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder
Laura Brandt, Jermaine D. Jones, Suky Martinez, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107859-107859
Open Access | Times Cited: 29
Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review
Dângela Layne Silva Lassi, André Malbergier, André Brooking Negrão, et al.
Brain Sciences (2022) Vol. 12, Iss. 11, pp. 1546-1546
Open Access | Times Cited: 18
Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial
Baltazar Gomez‐Mancilla, Kenneth M. Dürsteler, Marc Vogel, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 792
Closed Access
Logical fallacies and misinterpretations that hinder progress in translational addiction neuroscience
Justin C. Strickland, William W. Stoops, Matthew L. Banks, et al.
Journal of the Experimental Analysis of Behavior (2022) Vol. 117, Iss. 3, pp. 384-403
Open Access | Times Cited: 15
Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder
S. Stevens Negus, Matthew L. Banks
Neuropsychopharmacology (2020) Vol. 45, Iss. 12, pp. 1967-1973
Open Access | Times Cited: 23
Converging vulnerability factors for compulsive food and drug use
Katherine M. Serafine, Laura E. O’Dell, Eric P. Zorrilla
Neuropharmacology (2021) Vol. 196, pp. 108556-108556
Open Access | Times Cited: 19
Confronting the challenge of failed translation in medications development for substance use disorders
S. Stevens Negus, Matthew L. Banks
Pharmacology Biochemistry and Behavior (2021) Vol. 210, pp. 173264-173264
Open Access | Times Cited: 18
Medications Development for Treatment of Opioid Use Disorder
E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks
Cold Spring Harbor Perspectives in Medicine (2020) Vol. 11, Iss. 1, pp. a039263-a039263
Open Access | Times Cited: 20
The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals
Erin J. Campbell, Yvonne Bonomo, Adam Pastor, et al.
Pharmacology Research & Perspectives (2021) Vol. 9, Iss. 3
Open Access | Times Cited: 18
Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial
Sade E. Johns, Lori Keyser‐Marcus, Antonio Abbate, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 18
Human behavioral pharmacology of stimulant drugs: An update and narrative review
Ashley M. Strzelecki, Jessica Weafer, William W. Stoops
Advances in pharmacology (2022), pp. 77-103
Closed Access | Times Cited: 11
5HT‐2C agonist lorcaserin decreases cannabis self‐administration in daily cannabis smokers
Caroline A. Arout, Ziva D. Cooper, Stephanie Collins Reed, et al.
Addiction Biology (2021) Vol. 26, Iss. 4
Open Access | Times Cited: 13
Improving Translational Research Outcomes for Opioid Use Disorder Treatments
Jermaine D. Jones, Neil B. Varshneya, Thomas J. Hudzik, et al.
Current Addiction Reports (2021) Vol. 8, Iss. 1, pp. 109-121
Open Access | Times Cited: 11
Lorcaserin: Worthy of Further Insights? Results from Recent Research
Marianna Mazza, Georgios D. Kotzalidis, Giuseppe Marano, et al.
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 3, pp. 278-283
Closed Access | Times Cited: 4
Clinical neuropharmacology of cocaine reinforcement: A narrative review of human laboratory self‐administration studies
Sean D. Regnier, Joshua A. Lile, Craig R. Rush, et al.
Journal of the Experimental Analysis of Behavior (2022) Vol. 117, Iss. 3, pp. 420-441
Open Access | Times Cited: 7
Serotonin transporter protein in autopsied brain of chronic users of cocaine
Junchao Tong, Jeffrey H. Meyer, Isabelle Boileau, et al.
Psychopharmacology (2020) Vol. 237, Iss. 9, pp. 2661-2671
Open Access | Times Cited: 7
Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial
Glenn‐Milo Santos, Janet Ikeda, Phillip O. Coffin, et al.
PLoS ONE (2021) Vol. 16, Iss. 7, pp. e0254724-e0254724
Open Access | Times Cited: 7
Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys
Lisa R. Gerak, Charles P. France
Drug and Alcohol Dependence (2021) Vol. 227, pp. 108991-108991
Open Access | Times Cited: 7
Neural circuits controlling choice behavior in opioid addiction
Victoria N. Chang, Jamie Peters
Neuropharmacology (2022) Vol. 226, pp. 109407-109407
Open Access | Times Cited: 5
Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders
Ken W. Grasing, Kim Burnell, Alok De
Behavioural Pharmacology (2022) Vol. 33, Iss. 4, pp. 238-248
Open Access | Times Cited: 4
Heightened cocaine-seeking in male rats associates with a distinct transcriptomic profile in the medial prefrontal cortex
Christina R. Merritt, Ashley Smith, Kamil Khanipov, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 4
Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder
David J. McCann, Hegang H. Chen, Eric Devine, et al.
Drug and Alcohol Dependence (2023) Vol. 255, pp. 111063-111063
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top